BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24731854)

  • 21. The Mad side of the Max network: antagonizing the function of Myc and more.
    Rottmann S; Lüscher B
    Curr Top Microbiol Immunol; 2006; 302():63-122. PubMed ID: 16620026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
    Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
    EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
    Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
    Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drosophila Myc: A master regulator of cellular performance.
    Grifoni D; Bellosta P
    Biochim Biophys Acta; 2015 May; 1849(5):570-81. PubMed ID: 25010747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation.
    Raffeiner P; Hart JR; García-Caballero D; Bar-Peled L; Weinberg MS; Vogt PK
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6571-6579. PubMed ID: 32156728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myc, Max, and Mnt: molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis.
    Nakamura I; Roberts LR
    Gastroenterology; 2011 Jul; 141(1):32-4. PubMed ID: 21620848
    [No Abstract]   [Full Text] [Related]  

  • 28. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
    D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
    J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-induction of Mad1 and c-Myc in activated normal B lymphocytes.
    Ertesvåg A; Blomhoff HK; Beiske K; Naderi S
    Scand J Immunol; 2000 Jun; 51(6):565-70. PubMed ID: 10849366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
    Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
    Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-MYC targets the central oscillator gene Per1 and is regulated by the circadian clock at the post-transcriptional level.
    Repouskou A; Prombona A
    Biochim Biophys Acta; 2016 Apr; 1859(4):541-52. PubMed ID: 26850841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mnt: master regulator of the Max network.
    Nilsson JA; Cleveland JL
    Cell Cycle; 2004 May; 3(5):588-90. PubMed ID: 15107624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Myc/Max/Mad network and the transcriptional control of cell behavior.
    Grandori C; Cowley SM; James LP; Eisenman RN
    Annu Rev Cell Dev Biol; 2000; 16():653-99. PubMed ID: 11031250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo.
    James L; Eisenman RN
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10429-34. PubMed ID: 12149476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule inhibitors of the Myc oncoprotein.
    Fletcher S; Prochownik EV
    Biochim Biophys Acta; 2015 May; 1849(5):525-43. PubMed ID: 24657798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
    J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
    Mao B; Zhao G; Lv X; Chen HZ; Xue Z; Yang B; Liu DP; Liang CC
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1573-81. PubMed ID: 21807113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
    Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
    Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.